FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Zepbound is the newest GLP-1 medication to be approved by the Food and Drug Administration (FDA) for weight loss. It’s available only by prescription for people with a body mass index (BMI) of ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk ... The near-10% compound annual growth rate predicted by the analysts reflects the late-phase pipeline.

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Results from a separate trial that were released in 2022 showed patients taking a high dose of Lilly's (LLY.N), opens new tab Zepbound saw more than 20% weight loss. "The results give us greater ...

Novo Nordisk has also struggled to keep up with demand for its GLP-1 rivals to Mounjaro and Zepbound, which are marketed as Ozempic and Wegovy, respectively. In late October, the FDA listed the ...

The agency allowed the pharmacies and outsourcing facilities to compound, distribute ... to reverse FDA’s determination that Mounjaro and Zepbound are not in shortage, so Plaintiffs can claim ...